According to his yet to be published data, Schwartz said that the drug was shown to help “cure” people of the virus within just six days.
Maayan Jaffe-Hoffman
An Israeli tropical-disease expert says he has
new proof that a drug used to fight parasites in third-world countries could
help reduce the length of infection for people who contract coronavirus.
Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, last week completed a clinical trial of the US Food and Drug Administration-approved drug ivermectin, a broad-spectrum antiparasitic agent that has also been shown to fight viruses.
The double-blind, placebo-controlled study
included 100 people with mild to moderate cases of the disease who were not
hospitalized for the virus. It tested whether ivermectin could shorten the
viral shedding period, allowing them to test negative for coronavirus and leave
isolation in only a few days.
According to his still
unpublished data, Schwartz said the drug was shown to help “cure” people of the
virus within just six days. Moreover, the chances of testing negative for
coronavirus were three times higher for the group who received ivermectin than
the placebo, he told The Jerusalem Post.
“From a public-health point of
view, the majority of patients with corona are mild cases, and 90% of these
people are isolated outside of the hospital,” Schwartz said. “If you have any kind
of drug that can shorten the duration of the infectiousness of these patients, that would be
dramatic, as then they will not infect others.”
Moreover, instead of isolating
for a minimum of 10 days and maybe more, this period could be shortened,
benefiting the economy.
Finally, although Schwartz’s study did not focus on this, he said the results indicate that it is likely if the drug were given at the beginning of one’s illness, it could prevent deterioration and hospitalization.
Schwartz is currently
preparing the data from his study for publication. On Monday, he is scheduled
to present his findings to the Health Ministry and will also submit a report to
the FDA.
Since April, there have been
many trials and analyses suggesting the effectiveness of ivermectin against the
novel coronavirus. But only a handful have been conducted effectively as
double-blind, placebo-controlled tests such as Schwartz’s.
“There is insufficient data
for the COVID-19 Treatment Guidelines Panel to recommend either for or against
the use of ivermectin for the treatment of COVID-19,” the US National
Institutes of Health said in a statement last Thursday. “Results from
adequately powered, well-designed, and well-conducted clinical trials are
needed to provide more specific, evidence-based guidance on the role of
ivermectin in the treatment of COVID-19.”
However, NIH did verify that
for other indications, “ivermectin has been widely used and is generally well
tolerated.”
“Ivermectin is a chemical
therapeutic agent, and it has significant risks associated with it,” Hebrew
University of Jerusalem Prof. Ya’acov Nahmias told the Post.
“We should be very cautious
about using this type of medication to treat a viral disease that the vast
majority of the public is going to recover from even without this treatment,”
he said.
When Israel launched its mass
vaccination campaign, there were many who believed there would no longer be a
need for medication, Schwartz said.
“Now we know that this was an
illusion,” he said. “Even in Israel, not everyone is taking the vaccine. There
is quite a big population of youngsters under the age of 16 for whom it will be
at least months until we have a vaccine for them. And if you look worldwide,
vaccinating everyone will take a few years.”
Because ivermectin is
FDA-approved, its safety does not have to be proven, Schwartz said. Rather,
approval just needs to be received for its use in this new indication, he said.
Schwartz said he hopes the new
study will “be a cornerstone to get this permission.”
“The numbers are not high, but
they are convincing enough that they should open the gates for more studies and
for its preliminary use, especially when we don’t have anything else to offer,”
he said.
Maayan Jaffe-Hoffman, The Jerusalem Post, February 14, 2021 20:35
Relacionados:A Sadly Revealing Story
Auxiliar de Enfermagem francês: “... Eu me sentia tranquilo por dispor de azitromicina e cloroquina, pois evitavam casos graves!"
More evidence of the statistically significant antiviral impact of ivermectin in a double blinded Israeli Randomized Controlled Trial
Twitter censura página pró-tratamento precoce
Cinco perguntas para o médico Flávio Cadegiani, pesquisador do tratamento precoce
África do Sul aprova uso de ivermectina no combate à covid-19
Um terço dos médicos acredita no tratamento precoce, diz pesquisa
Nenhum comentário:
Postar um comentário
Não publicamos comentários de anônimos/desconhecidos.
Por favor, se optar por "Anônimo", escreva o seu nome no final do comentário.
Não use CAIXA ALTA, (Não grite!), isto é, não escreva tudo em maiúsculas, escreva normalmente. Obrigado pela sua participação!
Volte sempre!
Abraços./-